Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cervical screening and HPV testing principles

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Screening must not delay assessment of symptoms

Heavy active bleeding, haemodynamic disturbance, severe pelvic pain, pregnancy-related bleeding or a cervix that looks malignant belongs to an urgent diagnostic pathway, not routine screening recall.

Action: Assess stability and pregnancy where relevant, examine with consent, control major bleeding, and use acute gynaecology or the suspected-cancer pathway according to the finding rather than waiting for an HPV screening result.

Synopsis

Apply England's current primary HPV screening pathway accurately while separating preventive screening from investigation of symptoms, visible cervical disease and specialist surveillance.

  • Cervical screening is offered to asymptomatic women and people with a cervix to detect high-risk HPV and prevent cancer; it is not a diagnostic test for bleeding, pain or a visible lesion.
  • In England, the first invitation is sent at age 24.5 and routine screening covers ages 25 to 64; a routine primary hrHPV-negative result now sets a 5-year interval.
  • For qualifying tests taken on or after 1 July 2025, England uses a 5-year routine interval after hrHPV negativity; existing due dates were not moved retrospectively. Someone under 50 with hrHPV positivity in the preceding 5 years may receive a 3-year recall after a later negative result.
  • The laboratory tests the clinician-taken liquid-based sample for high-risk HPV first; cytology is performed only when hrHPV is detected, so an HPV-negative sample has no routine cytology report.
  • An hrHPV-positive result does not mean cancer. Reflex cytology separates immediate colposcopy referral from repeat HPV-based surveillance, while persistent infection drives escalation.
  • England began phased HPV self-testing on 25 August 2026 for invited underscreened or never-screened people aged 30 to 65 who had not attended after previous invitations; a kit cannot simply be requested outside that invitation route.
  • HPV vaccination greatly reduces risk but does not remove the need to accept screening invitations because vaccination does not prevent every oncogenic HPV infection or treat established infection.
  • Invitation and recall rules differ across England, Scotland, Wales and Northern Ireland; identify the national programme and follow the person's actual call-and-recall record.

    • Key red flags

    A cervix with an irregular, ulcerated, friable or bleeding mass requires a suspected-cancer pathway referral regardless of age, vaccination or the last screening result.

    Persistent postcoital or intermenstrual bleeding, blood-stained discharge, pelvic pain or unexplained weight loss requires diagnostic assessment even when screening is up to date.

    Bleeding with hypotension, tachycardia, syncope, severe anaemia symptoms or pregnancy possibility needs same-day acute assessment before preventive care.

    A person overdue after a previous abnormal result, treatment for CIN or cervical cancer may be on surveillance rather than routine recall and needs record reconciliation.

    Immunosuppression, including HIV, can alter screening or surveillance arrangements and should prompt confirmation of the programme-specific plan.

    Investigation priorities

    01
    Clinician-taken primary hrHPV testFirst step

    Detect oncogenic HPV in a cervical liquid-based screening sample within the national programme.

    Management branches

    InvitationConfirm eligibility and support informed attendance

    A person receives an invitation, asks whether screening is due or has no reliable recall record.

    1. Confirm that a cervix is present, identify the relevant UK national programme and retrieve the call-and-recall history rather than estimating from age alone.
    2. Explain primary HPV testing, possible reflex cytology and downstream outcomes, then address trauma, pain, disability, menopause, language and gender-related access needs.
    3. Arrange the programme-approved clinician sample or eligible invited self-test route and record consent, deferral or informed decline without removing future access.
    Open full textbook →Answer 2 questions
    Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • NHS Cervical Screening Programme policy
    • NHS cervical screening care pathway
    • NHS cervical screening pathway requirements
    • UKHSA HPV Green Book chapter
    • NICE NG12 gynaecological cancer referral
    • NHS England HPV self-testing launch 2026
    • NHS cervical screening sample-taker guidance

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom